Group 1 - The Hong Kong biotechnology stocks experienced a collective decline, with notable drops in several companies [1] - WuXi AppTec (02126) saw a decrease of 12.95%, closing at 4.840 [2] - BioNTech (06952) fell by 12.53%, with a latest price of 13.750 [2] Group 2 - Other companies such as Valiant (09887) and Beihai Kangcheng (01228) also reported significant declines of 9.93% and 9.75% respectively [2] - The decline extended to companies like Saint Noble (02257) and MIRXES (02629), which dropped by 9.64% and 8.43% [2] - Overall, the biotechnology sector is facing downward pressure, impacting multiple firms [1]

Group 1 - Hong Kong biopharmaceutical stocks weakened again in the afternoon on August 28, with WuXi AppTec and Bionet falling over 12% [1] - The decline in these stocks indicates a potential trend in the biopharmaceutical sector within the Hong Kong market [1] - The performance of these companies may reflect broader market sentiments and investor confidence in the biopharmaceutical industry [1]

Market Overview - The Hong Kong stock market experienced a collective decline in the morning session, with the Hang Seng Index falling by 0.66%, narrowly holding above 25,000 points, while the Hang Seng China Enterprises Index dropped by 0.86% and the Hang Seng Tech Index decreased by 1.04%, marking three consecutive days of decline [2][2][2] - Southbound capital recorded a net sell-off exceeding 10 billion HKD [2] Sector Performance - Major technology stocks, which serve as market indicators, showed collective weakness, particularly Meituan, which plummeted over 10% post-earnings, marking the worst performance. Alibaba and JD.com fell nearly 4%, while Baidu dropped over 1%. Xiaomi and Tencent also experienced declines [2][2][2] - The biopharmaceutical sector continued to decline due to impending drug tariffs, with innovative drug companies facing significant drops, including a more than 12% decline for BGI Genomics, alongside declines for Kangfang Bio, Zai Lab, WuXi Biologics, and BeiGene [2][2][2] - Chinese electric vehicle stocks in the US market also fell, leading to a collective drop in Hong Kong's new energy vehicle sector. Other sectors such as new consumption, steel, building materials, beer, heavy machinery, catering, and gambling stocks also saw declines [2][2][2] Positive Trends - Institutions are optimistic about the accelerated replacement of domestic chips, leading to a significant rise in semiconductor stocks, with SMIC surging over 8% and approaching historical highs [2][2][2] - Financial stocks, including domestic banks, Chinese brokerage firms, and domestic insurance stocks, generally performed actively, while oil and rare earth concept stocks saw widespread increases [2][2][2]

Core Viewpoint - The stock of Boan Biotechnology (06955) fell over 8% following the release of its interim results, indicating market concerns regarding its profitability despite revenue growth [1] Financial Performance - For the first half of the year, Boan Biotechnology reported revenue of RMB 393 million, an increase of 8.4% year-on-year [1] - Gross profit remained stable at RMB 283 million, showing no significant change compared to the previous year [1] - The profit attributable to the parent company was RMB 20.514 million, a decrease of 66.7% year-on-year [1] Product Sales - The increase in revenue was primarily driven by the sales of products (Boan's You Nuo, Boan's You Bei, and Bo Luo Jia), which grew by 15.9% to RMB 385.3 million for the six months ending June 30, 2024 [1] Regulatory Approval - On August 9, Boan Biotechnology announced that its self-developed product, Boan You Ping (Dulaglutide injection), received approval from the National Medical Products Administration for market launch [1] - This product is the world's first and currently the only approved biosimilar to Trulicity, with no other domestic Dulaglutide injections having entered the market approval application stage [1] - The commercialization of Boan You Ping in mainland China will be conducted in collaboration with Shanghai Pharmaceuticals Holding Co., Ltd. [1]

Core Viewpoint - The stock of Bohan Bio (06955) has dropped over 8% following the release of its interim results, reflecting investor concerns over declining profits despite revenue growth [1] Financial Performance - For the first half of the year, Bohan Bio reported revenue of RMB 393 million, an increase of 8.4% year-on-year [1] - Gross profit remained stable at RMB 283 million, showing no significant change compared to the previous year [1] - Profit attributable to the parent company decreased by 66.7% to RMB 20.514 million [1] Revenue Drivers - The increase in revenue was primarily driven by the sales of products (Bohyunuo, Bohyunbei, and Boluoga), which grew by 15.9% to RMB 385.3 million for the six months ending June 30, 2024 [1] Product Approval - On August 9, Bohan Bio announced that its self-developed product, Bohyunping (Dulaglutide injection), received approval from the National Medical Products Administration for use in blood sugar control in adult patients with type 2 diabetes [1] - Bohyunping is the first and currently the only approved biosimilar of Trulicity in the world, with no other domestic Dulaglutide injections having entered the market approval application stage [1] - The commercialization of Bohyunping in mainland China is being conducted in collaboration with Shanghai Pharmaceuticals Holding Co., Ltd. [1]

Core Viewpoint - The company reported a revenue of RMB 393.4 million for the six months ending June 30, 2025, representing an 8.4% year-on-year increase, while the net profit attributable to the parent company decreased by 66.7% to RMB 20.5 million [1][2]. Financial Performance - Revenue for the period was RMB 393.4 million, up from RMB 362.9 million in the same period last year [2]. - Gross profit remained relatively stable at RMB 282.6 million, compared to RMB 282.6 million in the previous year [2]. - The sales cost increased significantly to RMB 110.8 million from RMB 80.3 million, indicating a rise in operational expenses [2]. - Other income and gains decreased sharply to RMB 2.6 million from RMB 36.1 million [2]. - Research and development costs were reduced to RMB 58.6 million from RMB 85.8 million, reflecting a strategic focus on cost management [2]. - Administrative expenses slightly decreased to RMB 23.2 million from RMB 24.3 million [2]. - Selling and distribution expenses increased to RMB 159.8 million from RMB 134.2 million, indicating higher marketing efforts [2]. - Financial costs rose to RMB 19.5 million from RMB 12.6 million, impacting overall profitability [2]. Profitability Metrics - The profit before tax was RMB 20.5 million, down from RMB 61.7 million in the previous year [2]. - Basic earnings per share decreased to RMB 0.04 from RMB 0.12, reflecting the decline in net profit [2]. - Total comprehensive income for the period was RMB 20.4 million, significantly lower than RMB 61.6 million from the previous year [2].

Core Insights - The company reported a revenue of RMB 393 million for the six months ending June 30, 2025, representing an 8.4% year-on-year increase [1] - Gross profit remained relatively stable at RMB 283 million, showing no significant change compared to the previous period [1] - Net profit attributable to the parent company decreased by 66.7% to RMB 20.514 million, with basic earnings per share at RMB 0.04 [1] - The increase in revenue was primarily driven by a 15.9% growth in sales of key products (博优诺®, 博优倍®, and 博洛加®), totaling RMB 385.3 million [1]

Core Viewpoint - The company reported a revenue of 393 million RMB for the six months ending June 30, 2025, reflecting an 8.39% year-on-year increase, while the net profit attributable to shareholders decreased by 66.74% to 20.514 million RMB [1] Revenue Performance - The revenue increase was primarily driven by the sales growth of products (Bo Younuo, Bo Youbei, and Bo Luojia), which rose by 15.9% to 385 million RMB compared to the six months ending June 30, 2024 [1]

Core Points - The company reported a revenue of 393 million RMB for the six months ending June 30, 2025, representing an increase of 8.39% year-on-year [1] - Shareholder profit attributable to the company was 20.514 million RMB, a decrease of 66.74% compared to the previous year [1] - Basic earnings per share were 0.04 RMB [1] Revenue Analysis - The increase in revenue was primarily driven by the sales growth of products (博优诺®, 博优倍®, and 博洛加®), which rose by 15.9% to 385 million RMB compared to the six months ending June 30, 2024 [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部 或 任 何 部 分 內 容 而 產 生 或 因 依 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 Shandong Boan Biotechnology Co., Ltd. 山東博安生物技術股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：6955） 截 至2025年6月30日止六個月的中期業績公告 財務摘要 1. 收 入 截 至2025年6月30日 止 六 個 月，本 集 團 的 收 入 約 為 人 民 幣393.4百 萬 元， 較截至2024年6月30日止六個月的人民幣362.9百萬元增加約人民幣30.5 百 萬 元，同 比 增 長8.4%。該 增 加 主 要 是 由 於 產 品（博 優 諾®、博 優 倍®及 博 洛 加®）銷售較截至2024年6月30日止六個月持續增長15.9%至人民幣385.3 百 萬 元。 2. ...